Risk-Based Quality Management as a Survival Kit

From Idea to Implementation

(by Randy Ramin-Wright and Artem Andrianov)

DIA Global Forum: Efficient risk management becomes more than advice today, it becomes part of a survival kit for a modern pharmaceutical company.

Due to increasing trial complexity, regulatory scrutiny, competition for patients and high quality sites, the R&D returns in pharma have halved in the past 10 years.

Download the PDF-Dokument

By Artem Andrianov, Ph.D., MBA|2020-09-23T09:49:45+02:00August 26, 2015|Blog|0 Comments

About the Author: Artem Andrianov, Ph.D., MBA

Professional in the integration of data-driven Risk-based Quality Management (RBQM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, Health 2.0, DGGF, etc. 18+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RBQM research to new frontiers for CROs, pharma and biotech companies.